Read by QxMD icon Read

burkitt s leukemia

Dina S Soliman, Shehab Fareed, Einas Alkuwari, Halima El-Omri, Ahmad Al-Sabbagh, Amna Gameel, Mohamed Yassin
Discordant lymphoma is rare condition in which different types of malignant lymphomas occurring in different anatomic sites. The two diseases may present clinically as concurrent or sequential disease (10). Herein we are reporting a Pakistani female in her 60s, a carrier of hepatitis B virus with multiple comorbidities presented with cervical lymphadenopathy, diagnosed as Hodgkin's lymphoma, mixed cellularity. During the staging workup, the patient was discovered to have extensive bone marrow (BM) involvement by Burkitt leukaemia/lymphoma (BL)...
2016: Clinical Medicine Insights. Blood Disorders
I M Gordiienko, L M Shlapatska, L M Kovalevska, S P Sidorenko
UNLABELLED: Within B-cell lineage cell surface receptor CD150/SLAMF1 is broadly expressed starting from pre-B cells with upregulation toward plasma cells. However, expression of CD150 is rather limited on the surface of malignant B cells with the block of differentiation at the different stages of maturation. The aim of our work was to explore CD150 expression both on protein and mRNA levels with the emphasis on CD150 isoforms in malignant B-cell lines at the different stages of maturation in comparison with their normal B cell counterparts...
June 2016: Experimental Oncology
E Mandato, S Manni, F Zaffino, G Semenzato, F Piazza
Genetic mutations of oncogenes often underlie deranged cell growth and altered differentiation pathways leading to malignant transformation of B-lymphocytes. However, addiction to oncogenes is not the only drive to lymphoid tumor pathogenesis. Dependence on non-oncogenes, which act by propelling basic mechanisms of cell proliferation and survival, has also been recognized in the pathobiology of lymphoid leukemias, lymphomas and multiple myeloma. Among the growing number of molecules that may uphold non-oncogene addiction, a key place is increasingly being recognized to the serine-threonine kinase CK2...
April 4, 2016: Oncogene
Bryan A Bassig, Wing-Yan Au, Oscar Mang, Roger Ngan, Lindsay M Morton, Dennis K M Ip, Wei Hu, Tongzhang Zheng, Wei Jie Seow, Jun Xu, Qing Lan, Nathaniel Rothman
Clinical studies of lymphoid malignancies (LMs) have suggested that the descriptive patterns of LMs differ in East Asia compared to Western populations. However, there are very limited available data on population-based, subtype-specific incidence rates of LMs in the East Asian population, particularly in Chinese. Using data from the Hong Kong (HK) Cancer Registry and United States (U.S.) SEER Program, we calculated and compared age-adjusted incidence rates of LM subtypes in HK to those in Whites and Asians living in the U...
June 2016: Cancer Epidemiology
Xiufen Liu, Fabian Müller, Alan S Wayne, Ira Pastan
HA22 (Moxetumomab pasudotox) is a recombinant immunotoxin (RIT), composed of an anti-CD22 Fv fused to a truncated portion of Pseudomonas exotoxin A. HA22 is in clinical trials to treat patients with hairy cell leukemia and acute lymphoblastic leukemia (ALL). LMB-11 is an improved variant of HA22 with reduced immunogenicity, has a longer half-life in the blood and high activity in vitro and in a Burkitt lymphoma model in vivo Searching for RIT enhancing combination therapies, we found the protein kinase A inhibitor H89 to enhance LMB-11 and HA22 activity 5- to 10-fold on ALL cell lines and on patient-derived ALL samples...
May 2016: Molecular Cancer Therapeutics
Megan C Smith, Megan K Kressin, Eric Crawford, Xuan J Wang, Annette S Kim
B lymphoblastic leukemia is a B progenitor cell neoplasm with a range of immature immunophenotypes and several associated cytogenetic lesions. In contrast, Burkitt leukemia/lymphoma is a mature B lymphocyte neoplasm with a characteristic germinal center immunophenotype and MYC rearrangement. With modern immunophenotyping and cytogenetic methods, the distinction between these 2 entities is seldom ambiguous. Herein, we report a case of a 9-year-old white boy with circulating leukemic cells that demonstrate morphologic overlap between Burkitt leukemia and B lymphoblastic leukemia...
2015: Laboratory Medicine
Joo Y Song, Girish Venkataraman, Yuri Fedoriw, Alex F Herrera, Tanya Siddiqi, Mir B Alikhan, Young S Kim, Joyce Murata-Collins, Dennis D Weisenburger, Xueli Liu, Amy S Duffield
Burkitt lymphoma patients with bulky disease often have bone marrow involvement. However, leukemic presentation of Burkitt lymphoma in the absence of a mass (pure Burkitt leukemia; PBL) is uncommon. Both PBL and Burkitt lymphoma/leukemia, presenting with a tumor mass and marrow involvement (BLL), are considered stage IV disease, which is associated with a poor prognosis. However, there is limited information on the prognosis in adults with PBL because they have typically been included in cohorts of patients with BLL...
2016: Leukemia & Lymphoma
V Mühlbacher, T Haferlach, W Kern, M Zenger, S Schnittger, C Haferlach
Pretreatment cytogenetics is an important parameter for risk stratification and therapy approach in acute lymphoblastic leukemia (ALL). However, in up to 30% of cases, chromosome banding analysis (CBA) fails or reveals a normal karyotype. To characterize the subset of ALL with normal karyotype or failed CBA, we performed fluorescence in situ hybridization (FISH) or PCR for BCR-ABL1 and MLL rearrangements as well as array comparative genomic hybridization (aCGH) in 186 adult patients. We further carried out FISH for MYC in cases with Burkitt leukemia phenotype...
February 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
E A Bariakh, N G Tiurina, V I Vorob'ev, E G Gemdzhian, Ia K Mangasarova, G A Kliasova, A M Kovrigina, T N Obukhova, E E Zvonkov, M A VernIuk, A M Chervontseva, Iu Iu PolIakov, A E Misiurina, T T Valiev, V A Zherebtsova, A U Magomedova, G M Galstian, K V Iatskov, E S Nesterova, A I Vorob'ev, S K Kravchenko
AIM: To evaluate the efficiency and toxicity of the intensive Burkitt's lymphoma (BL) therapy protocol BL-M-04. SUBJECTS AND METHODS: A total of 70 patients diagnosed with BL, including 45 men and 25 women whose age was 15 to 62 years (median age 31 years), were followed up in 2003 to 2014. Stage I (according to S. Murphy) was diagnosed in 4 (5.7%) patients; II in 9 (12.9%), III in 25 (35.7%), IV in 11 (15.7%), and Burkitt's leukemia in 21 (30%). There were tumor involvements of the bone marrow and central nervous system in 23 (32...
2015: Terapevticheskiĭ Arkhiv
Véronique Minard-Colin, Laurence Brugières, Alfred Reiter, Mitchell S Cairo, Thomas G Gross, Wilhelm Woessmann, Birgit Burkhardt, John T Sandlund, Denise Williams, Marta Pillon, Keizo Horibe, Anne Auperin, Marie-Cécile Le Deley, Martin Zimmerman, Sherrie L Perkins, Martine Raphael, Laurence Lamant, Wolfram Klapper, Lara Mussolin, Hélène A Poirel, Elizabeth Macintyre, Christine Damm-Welk, Angelo Rosolen, Catherine Patte
Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even higher incidence in adolescents, and is primarily represented by only a few histologic subtypes. Dramatic progress has been achieved, with survival rates exceeding 80%, in large part because of a better understanding of the biology of the different subtypes and national and international collaborations. Most patients with Burkitt lymphoma and diffuse large B-cell lymphoma are cured with short intensive pulse chemotherapy containing cyclophosphamide, cytarabine, and high-dose methotrexate...
September 20, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
M Vankalakunti, A Rohan, S Vishwanath, S Rampure, R Bonu, K Babu, H S Ballal
Spectrum of causes for renal dysfunction in patients with hematolymphoid malignancy (excluding plasma cell dyscrasia) is varied. A retrospective evaluation of "native" renal biopsies referred to our institute during the period from January 2010 to December 2013 revealed 12 cases. Age ranged between 7 and 69 (median 54.5) years. All patients were males. The neoplasms included non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, Burkitt's lymphoma, intravascular lymphoma, Hodgkin lymphoma and chronic myeloid leukemia...
July 2015: Indian Journal of Nephrology
Mohammed Al-Hamadani, Thomas M Habermann, James R Cerhan, William R Macon, Matthew J Maurer, Ronald S Go
The World Health Organization classification of non-Hodgkin lymphoma (NHL) was introduced in 2001. However, its incorporation into clinical practice is not well-described. We studied the distribution of NHL subtypes in adults diagnosed from 1998 to 2011, evaluated time trends, geo-demographic correlates, and changes in 5-year overall survival (OS). We obtained data prospectively collected by the National Cancer Data Base, which covers 70% of US cancer cases. There were 596,476 patients diagnosed with NHL. The major subtypes were diffuse large B-cell (32...
September 2015: American Journal of Hematology
M Ibrahim, S U Abdullahi, F Hassan-Hanga, A Atanda
Background: Childhood cancers represent an important global public health problem. Survival is still dismal in most low income countries. Materials and Methods: A prospective study of childhood cancers diagnosed at AKTH, Kano was undertaken from January 2003 to December 2009 to determine the pattern, socio-economic and geographical features. Results: Malignant lymphomas constituted 46.5% of all cases, of which 30.1% were Burkitt's lymphoma, 9.8% were Non-Hodgkin (non Burkitt's) lymphoma and 6.6% were Hodgkin lymphoma...
July 2014: Indian Journal of Cancer
Elizabeth K Cahoon, Ruth M Pfeiffer, David C Wheeler, Juan Arhancet, Shih-Wen Lin, Bruce H Alexander, Martha S Linet, D Michal Freedman
Associations between ultraviolet radiation (UVR) exposure and non-Hodgkin lymphoma (NHL) have been inconsistent, but few studies have examined these associations for specific subtypes or across race/ethnicities. We evaluated the relationship between ambient UVR exposure and subtype-specific NHL incidence for whites, Hispanics and blacks in the United States for years 2001-2010 (n = 187,778 cases). Incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were calculated for UVR quintiles using Poisson regression...
March 1, 2015: International Journal of Cancer. Journal International du Cancer
Martina Gobec, Matevž Prijatelj, Jozo Delić, Tijana Markovič, Irena Mlinarič-Raščan
The EP4 receptor conveys growth-inhibitory effects in mature and immature B cells via NF-κB. Herein, the EP4 receptor was evaluated as a potential therapeutic target for leukemia and lymphoma, whose survival depends on the constitutive activity of NF-κB. Utilizing a pharmacological approach, we proved that the EP4 receptor induces caspase-mediated apoptosis in malignantly transformed B cells, with the most prominent effect being on Burkitt׳s lymphoma cells. Since the increased activation of NF-κB underlies multi-drug resistance phenomena, we modulated this signaling pathway via EP4 receptor triggering...
November 5, 2014: European Journal of Pharmacology
Lindsay M Morton, Susan L Slager, James R Cerhan, Sophia S Wang, Claire M Vajdic, Christine F Skibola, Paige M Bracci, Silvia de Sanjosé, Karin E Smedby, Brian C H Chiu, Yawei Zhang, Sam M Mbulaiteye, Alain Monnereau, Jennifer J Turner, Jacqueline Clavel, Hans-Olov Adami, Ellen T Chang, Bengt Glimelius, Henrik Hjalgrim, Mads Melbye, Paolo Crosignani, Simonetta di Lollo, Lucia Miligi, Oriana Nanni, Valerio Ramazzotti, Stefania Rodella, Adele Seniori Costantini, Emanuele Stagnaro, Rosario Tumino, Carla Vindigni, Paolo Vineis, Nikolaus Becker, Yolanda Benavente, Paolo Boffetta, Paul Brennan, Pierluigi Cocco, Lenka Foretova, Marc Maynadié, Alexandra Nieters, Anthony Staines, Joanne S Colt, Wendy Cozen, Scott Davis, Anneclaire J de Roos, Patricia Hartge, Nathaniel Rothman, Richard K Severson, Elizabeth A Holly, Timothy G Call, Andrew L Feldman, Thomas M Habermann, Mark Liebow, Aaron Blair, Kenneth P Cantor, Eleanor V Kane, Tracy Lightfoot, Eve Roman, Alex Smith, Angela Brooks-Wilson, Joseph M Connors, Randy D Gascoyne, John J Spinelli, Bruce K Armstrong, Anne Kricker, Theodore R Holford, Qing Lan, Tongzhang Zheng, Laurent Orsi, Luigino Dal Maso, Silvia Franceschi, Carlo La Vecchia, Eva Negri, Diego Serraino, Leslie Bernstein, Alexandra Levine, Jonathan W Friedberg, Jennifer L Kelly, Sonja I Berndt, Brenda M Birmann, Christina A Clarke, Christopher R Flowers, James M Foran, Marshall E Kadin, Ora Paltiel, Dennis D Weisenburger, Martha S Linet, Joshua N Sampson
BACKGROUND: Non-Hodgkin lymphoma (NHL) comprises biologically and clinically heterogeneous subtypes. Previously, study size has limited the ability to compare and contrast the risk factor profiles among these heterogeneous subtypes. METHODS: We pooled individual-level data from 17 471 NHL cases and 23 096 controls in 20 case-control studies from the International Lymphoma Epidemiology Consortium (InterLymph). We estimated the associations, measured as odds ratios, between each of 11 NHL subtypes and self-reported medical history, family history of hematologic malignancy, lifestyle factors, and occupation...
August 2014: Journal of the National Cancer Institute. Monographs
Lindsay M Morton, Joshua N Sampson, James R Cerhan, Jennifer J Turner, Claire M Vajdic, Sophia S Wang, Karin E Smedby, Silvia de Sanjosé, Alain Monnereau, Yolanda Benavente, Paige M Bracci, Brian C H Chiu, Christine F Skibola, Yawei Zhang, Sam M Mbulaiteye, Michael Spriggs, Dennis Robinson, Aaron D Norman, Eleanor V Kane, John J Spinelli, Jennifer L Kelly, Carlo La Vecchia, Luigino Dal Maso, Marc Maynadié, Marshall E Kadin, Pierluigi Cocco, Adele Seniori Costantini, Christina A Clarke, Eve Roman, Lucia Miligi, Joanne S Colt, Sonja I Berndt, Andrea Mannetje, Anneclaire J de Roos, Anne Kricker, Alexandra Nieters, Silvia Franceschi, Mads Melbye, Paolo Boffetta, Jacqueline Clavel, Martha S Linet, Dennis D Weisenburger, Susan L Slager
BACKGROUND: Non-Hodgkin lymphoma (NHL), the most common hematologic malignancy, consists of numerous subtypes. The etiology of NHL is incompletely understood, and increasing evidence suggests that risk factors may vary by NHL subtype. However, small numbers of cases have made investigation of subtype-specific risks challenging. The International Lymphoma Epidemiology Consortium therefore undertook the NHL Subtypes Project, an international collaborative effort to investigate the etiologies of NHL subtypes...
August 2014: Journal of the National Cancer Institute. Monographs
Todd M Gibson, Lindsay M Morton, Meredith S Shiels, Christina A Clarke, Eric A Engels
OBJECTIVE: HIV-infected people have greatly elevated risk of non-Hodgkin lymphoma (NHL), particularly the AIDS-defining NHL subtypes: diffuse large B-cell lymphoma, Burkitt lymphoma and primary lymphomas arising in the central nervous system. The goals of this analysis were to comprehensively describe risks of NHL subtypes, especially those not well studied, among HIV/AIDS patients; examine risks specifically in the HAART era; and distinguish risks in HIV-infected individuals prior to diagnosis with AIDS...
September 24, 2014: AIDS
Charuvaka Muvva, E R Azhagiya Singam, S Sundar Raman, V Subramanian
Bromodomains (BRDs) are a diverse family of evolutionarily conserved protein-interaction modules. Among various members of the bromodomain and extra terminal domain family, BRD4 is found to be an important target for many diseases such as cancer, acute myeloid leukemia, multiple myeloma, Burkitt's lymphoma, etc. Therefore, in this study an attempt has been made to screen compounds from NCI Diversity, Drug Bank and Toslab Databases targeting the Kac binding site of BRD4 using molecular docking, molecular dynamics simulations, MM-PB/GBSA binding free energy calculations and steered molecular dynamics simulations...
July 29, 2014: Molecular BioSystems
P Macor, E Secco, N Mezzaroba, S Zorzet, P Durigutto, T Gaiotto, L De Maso, S Biffi, C Garrovo, S Capolla, C Tripodo, V Gattei, R Marzari, F Tedesco, D Sblattero
The efficacy of antibody-based immunotherapy is due to the activation of apoptosis, the engagement of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity (CDC). We developed a novel strategy to enhance CDC using bispecific antibodies (bsAbs) that neutralize the C-regulators CD55 and CD59 to enhance C-mediated functions. Two bsAbs (MB20/55 and MB20/59) were designed to recognize CD20 on one side. The other side neutralizes CD55 or CD59. Analysis of CDC revealed that bsAbs could kill 4-25 times more cells than anti-CD20 recombinant antibody in cell lines or cells isolated from patients with chronic lymphocytic leukemia...
February 2015: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"